Cellectis S.A.
Cellectis S.A. (CMVLF) Financial Performance & Income Statement Overview
Review Cellectis S.A. (CMVLF) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Cellectis S.A. (CMVLF) Income Statement & Financial Overview
Review Cellectis S.A. CMVLF income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $10.65M | $12.72M | $16.20M | $8.06M |
| Cost of Revenue | $2.02M | $0.00 | $0.00 | -$1.44M |
| Gross Profit | $8.64M | $12.72M | $16.20M | $9.50M |
| Gross Profit Ratio | $0.81 | $1.00 | $1.00 | $1.18 |
| R&D Expenses | $21.93M | $20.87M | $23.83M | $23.52M |
| SG&A Expenses | $2.33M | $3.45M | $5.17M | $3.88M |
| Operating Expenses | $22.82M | $23.40M | $26.97M | $25.27M |
| Total Costs & Expenses | $24.83M | $23.40M | $26.97M | $25.27M |
| Interest Income | $2.91M | $3.57M | $2.75M | $2.77M |
| Interest Expense | $1.91M | $1.91M | $1.96M | $1.83M |
| Depreciation & Amortization | $4.93M | $5.83M | $4.72M | $4.73M |
| EBITDA | -$11.29M | $14.17M | -$16.48M | -$18.90M |
| EBITDA Ratio | -$1.06 | $1.11 | -$1.02 | -$2.34 |
| Operating Income | -$14.18M | -$10.68M | -$10.77M | -$17.21M |
| Operating Income Ratio | -$1.33 | -$0.84 | -$0.66 | -$2.14 |
| Other Income/Expenses (Net) | -$3.95M | $17.12M | -$12.35M | -$8.25M |
| Income Before Tax | -$18.13M | $6.44M | -$23.12M | -$25.46M |
| Income Before Tax Ratio | -$1.70 | $0.51 | -$1.43 | -$3.16 |
| Income Tax Expense | $1000.00 | $514000.00 | -$59000.00 | -$193000.00 |
| Net Income | -$18.13M | $5.92M | -$23.06M | -$25.27M |
| Net Income Ratio | -$1.70 | $0.47 | -$1.42 | -$3.13 |
| EPS | -$0.18 | $0.07 | -$0.26 | -$0.28 |
| Diluted EPS | -$0.18 | $0.07 | -$0.26 | -$0.28 |
| Weighted Avg Shares Outstanding | $100.16M | $89.85M | $89.85M | $89.85M |
| Weighted Avg Shares Outstanding (Diluted) | $100.16M | $89.85M | $89.85M | $89.85M |
Over the past four quarters, Cellectis S.A. demonstrated steady revenue growth, increasing from $8.06M in Q2 2024 to $10.65M in Q1 2025. Operating income reached -$14.18M in Q1 2025, maintaining a consistent -133% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$11.29M, reflecting operational efficiency. Net income dropped to -$18.13M, with EPS at -$0.18. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan